3 results
Approved WMOCompleted
Primary:Assess the safety of repeat doses of serelaxin in chronic heart failureSecondary:- Assess the incidence rate of adverse events of special interest, indicative of hypersensitivity reactions- Assess the safety and tolerability of repeated…
Approved WMOCompleted
Primary Objective:To demonstrate that serelaxin is superior to placebo in reducing CV death in AHF patients during a follow-up period of 180 days.To demonstrate that serelaxin is superior to placebo in reducing worsening heart failure through Day…
Approved WMOCompleted
To determine the safety, tolerability and pharmacokinetics of an 18-hour i.v. infusion of CLR325 in stable heart failure patients.